The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

BackgroundBoth anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb) have been approved for the third line treatment of metastatic non-small cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatmen...

Full description

Bibliographic Details
Main Authors: Chongya Zhai, Xiaoling Zhang, Lulu Ren, Liangkun You, Qin Pan, Hongming Pan, Weidong Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
NSCLC
anlotinib hydrochloride
third line of therapy
TP53
EGFR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.619010/full

Similar Items

Similar Items